# Neo-adjuvant Immunotherapy Master Trial for Localized Cancers

> **NCT07262489** · PHASE2 · RECRUITING · sponsor: **UNICANCER** · enrollment: 200 (estimated)

## Conditions studied

- Localized Cancer

## Interventions

- **DRUG:** Each therapeutic NEOREM sub-protocol will mention the description of intervention

## Key facts

- **NCT ID:** NCT07262489
- **Lead sponsor:** UNICANCER
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-21
- **Primary completion:** 2029-11
- **Final completion:** 2034-11
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07262489

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07262489, "Neo-adjuvant Immunotherapy Master Trial for Localized Cancers". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07262489. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*